Published in Nat Biotechnol on March 24, 2003
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther (2008) 2.69
Lung transplantation: opportunities for research and clinical advancement. Am J Respir Crit Care Med (2005) 1.85
Oxidant stress regulatory genetic variation in recipients and donors contributes to risk of primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg (2014) 1.48
A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med (2007) 1.39
Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. J Control Release (2010) 1.27
Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis. Nat Med (2016) 1.26
Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials (2007) 1.17
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood (2007) 1.14
Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J Pharmacol Exp Ther (2009) 1.11
PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J (2010) 1.11
Targeted delivery of therapeutics to endothelium. Cell Tissue Res (2008) 1.10
Catalase and superoxide dismutase conjugated with platelet-endothelial cell adhesion molecule antibody distinctly alleviate abnormal endothelial permeability caused by exogenous reactive oxygen species and vascular endothelial growth factor. J Pharmacol Exp Ther (2011) 1.07
Nanocarriers for vascular delivery of antioxidants. Nanomedicine (Lond) (2011) 1.06
Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J Control Release (2008) 1.06
Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano (2011) 1.03
Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med (2009) 1.03
Dynamic factors controlling targeting nanocarriers to vascular endothelium. Curr Drug Metab (2012) 1.02
Collaborative enhancement of antibody binding to distinct PECAM-1 epitopes modulates endothelial targeting. PLoS One (2012) 0.98
Targeted modulation of reactive oxygen species in the vascular endothelium. J Control Release (2011) 0.97
Antioxidant enzyme gene transfer for ischemic diseases. Adv Drug Deliv Rev (2009) 0.90
Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J Control Release (2010) 0.88
Anti-inflammatory effect of targeted delivery of SOD to endothelium: mechanism, synergism with NO donors and protective effects in vitro and in vivo. PLoS One (2013) 0.87
Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium. J Control Release (2007) 0.87
Targeted interception of signaling reactive oxygen species in the vascular endothelium. Ther Deliv (2012) 0.87
Loading PEG-catalase into filamentous and spherical polymer nanocarriers. Pharm Res (2008) 0.87
PECAM-1 isoforms, eNOS and endoglin axis in regulation of angiogenesis. Clin Sci (Lond) (2015) 0.85
Nanoparticle-mediated catalase delivery protects human neurons from oxidative stress. Cell Death Dis (2013) 0.84
Targeting antioxidant and antithrombotic biotherapeutics to endothelium. Semin Thromb Hemost (2010) 0.83
Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. Biomaterials (2014) 0.83
Targeting and imaging signature caveolar molecules in lungs. Proc Am Thorac Soc (2009) 0.81
Protein kinase G increases antioxidant function in lung microvascular endothelial cells by inhibiting the c-Abl tyrosine kinase. Am J Physiol Cell Physiol (2014) 0.81
Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation. J Control Release (2014) 0.81
Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation. AAPS J (2009) 0.80
Primary graft dysfunction: lessons learned about the first 72 h after lung transplantation. Curr Opin Organ Transplant (2015) 0.78
European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biol (2017) 0.77
Targeted endothelial nanomedicine for common acute pathological conditions. J Control Release (2015) 0.77
Catalase-coupled gold nanoparticles: comparison between the carbodiimide and biotin-streptavidin methods. Acta Biomater (2011) 0.77
Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles. Bioconjug Chem (2016) 0.75
The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice. Physiol Rep (2015) 0.75
Modifications of microvascular EC surface modulate phototoxicity of a porphycene anti-ICAM-1 immunoconjugate; therapeutic implications. Langmuir (2013) 0.75
Targeting delivery of drugs in the vascular system. Int J Transp Phenom (2011) 0.75
Acute administration of catalase targeted to ICAM-1 attenuates neuropathology in experimental traumatic brain injury. Sci Rep (2017) 0.75
Novel Insights into the PKCβ-dependent Regulation of the Oxidoreductase p66Shc. J Biol Chem (2016) 0.75
Taking up the cudgels for the traditional reactive oxygen and nitrogen species detection assays and their use in the cardiovascular system. Redox Biol (2017) 0.75
Targeting the vascular and perivascular niches as a regenerative therapy for lung and liver fibrosis. Sci Transl Med (2017) 0.75
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med (2008) 4.70
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 4.65
Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest (2007) 3.63
The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo. Nat Immunol (2011) 3.04
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther (2008) 2.69
Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med (2006) 2.69
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci (2003) 2.34
Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. J Clin Invest (2006) 2.33
Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg (2002) 2.19
Oxygen microscopy by two-photon-excited phosphorescence. Chemphyschem (2008) 2.17
Tumor-associated neutrophils: friend or foe? Carcinogenesis (2012) 2.15
Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg (2010) 2.06
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol (2003) 2.03
De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol (2008) 1.95
Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med (2004) 1.95
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol (2011) 1.93
Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther (2006) 1.93
Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res (2005) 1.86
Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg (2002) 1.86
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation (2008) 1.84
Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol (2005) 1.81
Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thorac Cardiovasc Surg (2003) 1.80
A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res (2007) 1.78
Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol (2009) 1.74
PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol (2003) 1.74
MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation. Circ Res (2013) 1.67
NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest (2005) 1.65
Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol Ther (2003) 1.65
Cutting edge: Acute lung allograft rejection is independent of secondary lymphoid organs. J Immunol (2009) 1.64
ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. Am J Respir Crit Care Med (2011) 1.62
Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol (2005) 1.61
ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood (2004) 1.58
Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium. Arterioscler Thromb Vasc Biol (2012) 1.55
Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation (2007) 1.54
Advanced drug delivery systems that target the vascular endothelium. Mol Interv (2006) 1.54
Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol (2003) 1.54
Potential for detrimental hyperinflation after lung transplantation with application of negative pleural pressure to undersized lung grafts. J Thorac Cardiovasc Surg (2003) 1.54
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res (2011) 1.53
Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proc Natl Acad Sci U S A (2010) 1.53
Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion. Am J Physiol Heart Circ Physiol (2004) 1.52
Sternoclavicular joint infection: a comparison of two surgical approaches. Ann Thorac Surg (2011) 1.52
Inhibition of nuclear factor kappaB by IkappaB superrepressor gene transfer ameliorates ischemia-reperfusion injury after experimental lung transplantation. J Thorac Cardiovasc Surg (2005) 1.52
Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol (2010) 1.51
Stem cell mobilization by hyperbaric oxygen. Am J Physiol Heart Circ Physiol (2005) 1.51
A prospective evaluation of lung volume reduction surgery in 200 consecutive patients. Chest (2003) 1.51
Variation in the myosin light chain kinase gene is associated with development of acute lung injury after major trauma. Crit Care Med (2008) 1.50
Benefits of resection for metachronous lung cancer. J Thorac Cardiovasc Surg (2004) 1.50
Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival. Eur J Cardiothorac Surg (2008) 1.50
Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol (2003) 1.50
Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol (2010) 1.49
CCL2 blockade augments cancer immunotherapy. Cancer Res (2009) 1.48
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res (2007) 1.47
Prevalence of benign disease in patients undergoing resection for suspected lung cancer. Ann Thorac Surg (2006) 1.46
The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest (2010) 1.46
The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation (2005) 1.46
Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology (2005) 1.45
Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest (2013) 1.42
3D network model of NO transport in tissue. Med Biol Eng Comput (2011) 1.42
Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant (2010) 1.41
Gene expression profiling of the early pulmonary response to hyperoxia in mice. Am J Respir Cell Mol Biol (2003) 1.41
Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One (2012) 1.40
Nonoperative management of large tracheal injuries. J Thorac Cardiovasc Surg (2008) 1.40
Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res (2006) 1.40
Results of lung volume reduction surgery in patients meeting a national emphysema treatment trial high-risk criterion. J Thorac Cardiovasc Surg (2004) 1.39
Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat (2012) 1.39
Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res (2008) 1.38
Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant (2011) 1.37
Outcomes after resection of giant emphysematous bullae. Ann Thorac Surg (2004) 1.33
PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosis. Blood (2003) 1.33
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest (2014) 1.33
Maintenance of airway epithelium in acutely rejected orthotopic vascularized mouse lung transplants. Am J Respir Cell Mol Biol (2007) 1.33
Bronchial fenestration improves expiratory flow in emphysematous human lungs. Ann Thorac Surg (2003) 1.32
Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg (2010) 1.32
Flow dynamics, binding and detachment of spherical carriers targeted to ICAM-1 on endothelial cells. Biorheology (2009) 1.32
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res (2008) 1.32
Induction of IL-10 suppressors in lung transplant patients by CD4+25+ regulatory T cells through CTLA-4 signaling. J Immunol (2006) 1.31
Urinary volatile compounds as biomarkers for lung cancer: a proof of principle study using odor signatures in mouse models of lung cancer. PLoS One (2010) 1.31
Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant (2005) 1.31
Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood (2002) 1.30
In vivo imaging of 64Cu-labeled polymer nanoparticles targeted to the lung endothelium. J Nucl Med (2007) 1.30
Orthotopic mouse lung transplantation as experimental methodology to study transplant and tumor biology. Nat Protoc (2009) 1.30
Lymph node evaluation in video-assisted thoracoscopic lobectomy versus lobectomy by thoracotomy. Ann Thorac Surg (2010) 1.29
Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther (2005) 1.29
Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J Pharmacol Exp Ther (2008) 1.28